Sutro Biopharma STRO Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Sutro Biopharma’s reported figures.
Based on the most recent quarter.
The official record: Sutro Biopharma’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's debt-to-equity?
- Sutro Biopharma (STRO) reported debt-to-equity of 0.5× in Q4 2024.
- How has Sutro Biopharma's debt-to-equity changed year-over-year?
- Sutro Biopharma's debt-to-equity increased by 130.9% year-over-year, from 0.2× to 0.5×.
- What is the long-term trend for Sutro Biopharma's debt-to-equity?
- Over 4 years (2020 to 2024), Sutro Biopharma's debt-to-equity has grown at a 32.9% compound annual growth rate (CAGR), from 0.2× to 0.5×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.